Renaissance Technologies’s Hemab Therapeutics COAG Stock Holding History

Renaissance Technologies’s Portfolio COAG Stock Details COAG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$2.08M	Buy	+67,542	New	+$2.96M	﹤0.01%	1940

Other funds holding COAG

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Capital International Investors Los Angeles, California $483B AUM 27.72% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.23B AUM 121.47% 1-Year Est. Return

JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Ensign Peak Advisors Salt Lake City, Utah $60.6B AUM 33.98% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Swiss National Bank Zurich, Switzerland $189B AUM 37.1% 1-Year Est. Return

Renaissance Technologies's COAG Position: Q3 2026 in Review

Renaissance Technologies opened a new position in Hemab Therapeutics (COAG) in Q3 2026: 67,542 shares worth $2.08M. The stake represents ﹤0.01% of the portfolio and ranks #1940 among its holdings.

31 funds tracked by Wall St. Rank hold COAG as of Q3 2026.

Renaissance Technologies held 67,542 shares of Hemab Therapeutics worth $2.08M as of Q3 2026.
Hemab Therapeutics was a new Renaissance Technologies position in Q3 2026.
Hemab Therapeutics made up ﹤0.01% of Renaissance Technologies's portfolio in Q3 2026, its #1940 holding.
31 funds tracked by Wall St. Rank held Hemab Therapeutics as of Q3 2026.

Based on Renaissance Technologies's 13F filing for Q3 2026, filed 12 Nov 2026.